EIF4E and cancer: Ribavirin is already known to be effective in cancer therapy; it targets an oncogene, the eukaryotic translation initiation factor eIF4E, elevated in approximately 30% of cancers, including many leukemias and lymphomas, breast, esophagea, and ovarian cancers.